Rimonabant treatment for 12 weeks in obese women with polycystic ovarian syndrome resulted in increased circulating levels of VEGF however, the treatment did not alter TNF-α, IL-1β, IL-2, and IL-6 [30], which is in contrast to our results following AM251 treatment. This evidence concerns the gene IL6 and polycystic ovary syndrome.